EA Pharma

Executive Summary

EA Pharma is a Japan-based specialty pharmaceutical company exclusively focused on gastrointestinal and hepatological diseases. Formed in 2016 through the integration of Eisai's and Ajinomoto's gastrointestinal businesses, the company combines over 60 years of expertise with proprietary amino acid technology to develop, manufacture, and commercialize therapies. With a full value chain spanning R&D to sales, EA Pharma targets unmet medical needs in conditions such as inflammatory bowel disease (IBD) and other GI disorders. The company has a portfolio of marketed products and a pipeline of novel candidates leveraging amino acid-based approaches.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for novel IBD therapy60% success
• Q1 2027Regulatory filing for hepatology drug candidate70% success
• TBDStrategic partnership or licensing deal for early-stage asset50% success